Salute e Benessere
Pulnovo Medical Announces First Enrollment in Portugal for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease
said, "PADN technology shows great potential in treating pulmonary hypertension associated with left heart disease. We are delighted to be the first in Europe to participate in this global clinical study. Our team is confident in this project and looks forward to bringing more treatment options to European pulmonary hypertension patients through this study. PADN is not only a new treatment method but also brings new hope to patients suffering from pulmonary hypertension."
said, "The PADN global multicenter clinical study is one of our key projects dedicated to innovative treatment technologies in the cardiovascular field. As an emerging treatment, PADN has enormous potential and prospects. The post-operative results of the first overseas application of PADN reflect the academic borderlessness of the moment. In the future, we will continue to firmly advance our global business, steadily promoting the teaching and learning of PADN technology. "
said, "We are proud to have successfully completed the first enrollment in the European multicenter clinical study of PADN in Portugal , marking the acceleration of our technology's global progress. We will continue to promote the global application of PADN, allowing more patients to benefit from this innovative therapy."